Thursday, April 10, 2025, Denver, Colorado, 6:00 AM – 7:30 AM Mountain Time (8:00 AM – 9:30 AM Eastern Time)
Understanding the Current Paradigm and New Approaches in the Care of Patients with Chronic Myeloid Leukemia
A Complimentary NCPD Symposium Held During the 50th Annual ONS Congress
Event Details
Hyatt Regency Denver
at Colorado Convention Center
650 15th Street
Denver, Colorado
Hotel Phone: (303) 436-1234
Program Schedule — Mountain Time
5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting
Meeting Room
Capitol Ballroom (Fourth Floor)
Ilene Galinsky, RN, BSN, MSN, ANP-C
Senior Adult Research Program Nurse Practitioner
Adult Leukemia Division
Dana-Farber Cancer Institute
Boston, Massachusetts
Michael J Mauro, MD
Director, Chronic Myeloid Leukemia Program
Attending Physician, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Neil P Shah, MD, PhD
Edward S Ageno Distinguished Professor in Hematology/Oncology
Director, UCSF Molecular Medicine Residency Program
Chair, National Comprehensive Cancer Network CML Guidelines Panel
University of California, San Francisco
San Francisco, California
Sara M Tinsley-Vance, PhD, APRN, AOCN
Nurse Practitioner and Researcher
Moffitt Cancer Center
Tampa, Florida
Meeting space has been assigned to provide a satellite symposium supported by Novartis during the Oncology Nursing Society’s (ONS) 50th Annual Congress, April 9-13, 2025 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Agenda
5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting
Biology and Principles of Treatment of Chronic Myeloid Leukemia (CML)
- Pathogenesis of CML; role of BCR::ABL1 translocations in disease development
- Natural history of CML; distinctions between chronic-phase (CP), accelerated-phase and blast-phase disease
- Long-term prognosis and goals of care for CP-CML; achievement of treatment-free remission as a potential long-term objective
- Educating patients regarding response milestones and required follow-up with CML therapy
Role of Tyrosine Kinase Inhibitors (TKIs) as Initial Treatment for CP-CML
- Pharmacologic similarities and differences among first-generation (imatinib) and second-generation (dasatinib, nilotinib, bosutinib) TKIs; implications for the efficacy and tolerability of these agents
- Long-term outcomes observed with approved first- and second-generation TKIs in patients with newly diagnosed CP-CML
- Clinical and biological factors (eg, patient age, comorbidities, concomitant medications, Sokal risk score, desire for a treatment-free remission) influencing the selection of a front-line TKI for patients with CML
- Feasibility of TKI discontinuation for patients with a sustained response to therapy; identification of appropriate candidates for this strategy
Current Role of Asciminib for Newly Diagnosed CP-CML
- Mechanism of action of asciminib; similarities to and differences from other TKIs employed in the management of CML
- Published efficacy and safety findings with asciminib versus standard first-line TKIs for newly diagnosed CML
- Comparative depth of response with asciminib versus TKIs; implications for patients seeking to achieve a treatment-free remission
- FDA approval of asciminib for newly diagnosed CP-CML and its optimal integration into treatment in this setting
Management of CP-CML After Failure of Initial Therapy
- Spectrum of BCR::ABL1 mutations, including the T315I mutation, that confer resistance to TKI therapy; role of gene expression profiling in informing therapeutic selection in later lines
- Selection and sequencing of second- and third-generation TKIs for patients experiencing disease progression after initial TKI therapy
- Key efficacy and safety findings with asciminib for CP-CML previously treated with 2 or more TKIs and in patients with T315I-mutated disease
- Selection of appropriate patients with progressive/resistant CP-CML to receive asciminib
Tolerability/Toxicity Profile of BCR::ABL1 TKIs in CML
- Spectrum, frequency and severity of class-effect and agent-specific adverse events (AEs) documented with first-, second- and third-generation TKIs for patients with CML
- Optimal monitoring of complete blood counts, blood chemistry and cardiac, hepatic and renal function in patients with CML receiving TKI therapy
- Guideline-recommended algorithms for the management of toxicities from TKIs
- Role of switching to an alternative TKI for patients who are experiencing unacceptable toxicity
Other Practical Considerations with TKIs for CML
- Approved dosing schedules of imatinib, dasatinib, nilotinib, bosutinib and ponatinib; patient populations for whom an alternative dose or schedule may be indicated
- Recommendations regarding the timing of food intake relative to TKI dosing
- Documented drug-drug interactions affecting the use of concomitant medications and/or supplements with TKIs
- Strategies to monitor for adherence in patients with CML receiving oral therapy
Incidence and Management of Side Effects with Asciminib
- Spectrum, frequency and severity of common and serious AEs observed with asciminib (eg, myelosuppression, hypertension, cardiovascular events, gastrointestinal toxicity, musculoskeletal pain, pancreatitis)
- Comparative tolerability/toxicity profile of asciminib and TKIs for patients with CML
- Recommended pretreatment evaluations and lab assessments to monitor for asciminib-associated AEs
- Strategies to prevent and manage treatment-related AEs with asciminib
Other Practical Considerations with Asciminib
- Approved starting dose of asciminib for patients with CML with and without T315I mutations
- Recommended timing of food intake relative to asciminib dosing
- Rationale for avoiding concomitant use of asciminib and statins
- Other potential drug-drug interactions with asciminib
CE Information
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic myeloid leukemia (CML).
Learning Objectives
Upon completion of this activity, participants should be able to
- Evaluate factors, including age, comorbidities, personal preferences and side-effect profile, that contribute to the selection and sequencing of therapies for chronic-phase CML, and counsel patients regarding personalized treatment recommendations.
- Assess the means by which tyrosine kinase inhibitors (TKIs) inhibit CML growth and progression, and recollect which of these agents are available to patients with each phase of the disease.
- Interrogate available data on the feasibility of TKI discontinuation for patients with a sustained response to therapy, and identify appropriate candidates for this approach.
- Review the mechanism of action of and published efficacy and safety data with STAMP (specifically targeting the ABL myristoyl pocket) inhibitors for CML, and appreciate the current role of these agents in the management of newly diagnosed and relapsed/refractory disease.
- Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapeutic agents commonly employed for patients with CML to support quality of life and continuation of treatment.
Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2025/CML/ILNA.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.
Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Tinsley-Vance has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Ms Galinsky — Advisory Committees: Autolus Therapeutics, Blueprint Medicines, Bristol Myers Squibb, GSK, Novartis; Consulting Agreements: Novartis. Dr Mauro — Advisory Committees and Consulting Agreements: Bristol Myers Squibb, Enliven Therapeutics, Novartis, Takeda Pharmaceuticals USA Inc, Terns Pharmaceuticals; Contracted Research: Enliven Therapeutics, Novartis, Sun Pharma Advanced Research Company (SPARC), Sun Pharmaceutical Industries Ltd, Terns Pharmaceuticals. Dr Shah — Contracted Research: Kumquat Biosciences; Honoraria: Novartis (Delphi panel).
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by an educational grant from Novartis.
Location
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room
Capitol Ballroom (Fourth Floor)
The Hyatt Regency Denver at Colorado Convention Center is the headquarters hotel for the 2025 ONS Congress and is adjacent to the Colorado Convention Center.
Registration
There is no registration fee for this event. For the in-person symposium in Denver, preregistration is required as seating is limited.
NOTICE:
Registration for this event is independent of registration for the 2025 ONS Congress.
Please note, onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com.
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
REGISTRATION FOR WEBCAST »Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.